PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149069
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149069
Immunomodulators Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of immunomodulators Market
The global immunomodulators market size was valued at USD 250.69 billion in 2025 and is projected to grow from USD 269.15 billion in 2026 to USD 475.04 billion by 2034, registering a CAGR of 7.36% during 2026-2034. North America dominated the global market with a 38.32% share in 2025, supported by the high prevalence of autoimmune and chronic diseases, strong pharmaceutical research, clinical development, and product launches.
Immunomodulators are medicines that regulate immune-system activity by either suppressing or stimulating immune responses. Immunosuppressants are widely used for autoimmune disorders and to prevent organ rejection following transplantation, while immunostimulants include vaccines, antibodies, and other therapies that enhance immune responses. Increasing research into multiple sclerosis, rheumatoid arthritis, Crohn's disease, cancer, respiratory disorders, and other conditions is supporting demand for advanced immunomodulatory therapies.
Market Definition and Scope
The immunomodulators market covers pharmaceutical products that modify immune-system activity. The market is broadly classified into immunosuppressants and immunostimulants, with applications across oncology, respiratory diseases, HIV, autoimmune disorders, transplantation, and other medical conditions. The market also includes products developed and supplied through pharmaceutical and biotechnology companies, healthcare facilities, and related healthcare channels.
Market Dynamics
Drivers
The increasing prevalence of autoimmune diseases is a major factor driving market growth. Conditions such as multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease create significant demand for therapies that can regulate abnormal immune responses. Expanding clinical trials and the development of new immunotherapeutic agents are also contributing to the growing product pipeline.
The strong drug pipeline provides additional growth opportunities. Pharmaceutical and biotechnology companies are investing in combination therapies, biologics, targeted treatments, and novel immunomodulators to address unmet medical needs. Increasing research into cancer immunotherapy is also broadening the potential applications of immune-modulating medicines.
Trends
Robust research and development is a major trend in the market. Companies are increasingly focusing on immunotherapy, targeted drug therapy, monoclonal antibodies, and advanced treatments for cancer and autoimmune disorders. Strategic collaborations and partnerships are helping companies accelerate clinical development and commercialization.
Restraints
Adverse effects associated with immunomodulatory drugs can restrict market expansion. Immunosuppressive therapies may increase the risk of infections and other complications, while some treatments can cause fatigue, gastrointestinal problems, skin disorders, and other side effects. In addition, stringent regulatory requirements for clinical studies and product approvals can increase development timelines and costs.
Impact of COVID-19
The COVID-19 pandemic had a positive impact on the immunomodulators market in several areas because of increased demand for medicines and greater attention toward immune-related treatments. Pharmaceutical companies strengthened supply-chain management, manufacturing capabilities, quality control, and research activities to maintain product availability. The pandemic also encouraged research into immune-modulating approaches and potential supportive therapies.
Segmentation Analysis
By Product Type
The market is segmented into immunosuppressants and immunostimulants. Immunosuppressants held the largest market share, supported by their broad use in autoimmune diseases and transplantation. The immunostimulants segment is expected to witness strong growth as demand increases for vaccines, antibodies, and therapies designed to enhance immune responses.
By Application
Applications include oncology, respiratory, HIV, and others, with the other category covering conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. The respiratory segment is expected to account for a 37.9% share in 2025, while increasing cancer prevalence and growing adoption of immunotherapy are supporting the oncology segment.
Regional Insights
North America
North America generated USD 61.91 billion in 2025 and accounted for a 38.32% market share. High disease prevalence, strong pharmaceutical infrastructure, clinical research, and the presence of major market players support the region's leading position. The U.S. represents the largest contributor within the region.
Europe
Europe is an important market supported by pharmaceutical R&D investments and increasing sales of immunosuppressant drugs. The region is projected to grow at a CAGR of 6.2% during the forecast period.
Asia Pacific
Asia Pacific is projected to record strong growth, supported by increasing clinical studies, expanding healthcare infrastructure, and a growing geriatric population. China is projected to register a CAGR of 7.00%, while the immunomodulators market in Japan is expected to reach USD 7.70 billion in 2025.
Middle East & Africa and Latin America
These regions are expected to experience comparatively slower growth due to lower adoption of expensive therapies, limited healthcare infrastructure, and fewer product approvals in some developing countries.
Competitive Landscape
Major companies operating in the immunomodulators market include F. Hoffmann-La Roche Ltd., Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., and Eli Lilly and Company. Companies are focusing on R&D, strategic acquisitions, product launches, clinical development, and regulatory approvals to expand their portfolios.
Report Coverage
The immunomodulators market report covers market size and forecast, product types, applications, regional markets, leading companies, market trends, growth drivers, restraints, competitive developments, and industry opportunities. It also evaluates the impact of clinical research, drug pipelines, regulatory factors, and increasing demand for advanced immune-modulating therapies.
Conclusion
The global immunomodulators market is expected to expand from USD 250.69 billion in 2025 to USD 269.15 billion in 2026 and reach USD 475.04 billion by 2034, at a CAGR of 7.36%. Rising autoimmune and chronic disease prevalence, expanding clinical research, strong drug pipelines, and increasing applications in oncology and respiratory diseases are supporting market development. North America remains the leading regional market, while Asia Pacific is expected to experience strong growth during the forecast period.
Unit Value (USD Billion)
Segmentation Product Type; Application; and Region
By Product Type
- Immunosuppressants
- Immunostimulants
By Application
- Respiratory
- Oncology Multiple Sclerosis
- Others
By Geography
- North America
- By Product Type
- By Application
- By Country
- USA (By Product Type)
- Canada (By Product Type)
- Europe
- By Product Type
- By Application
- By Country
- UK (By Product Type)
- Germany (By Product Type)
- France (By Product Type)
- Italy (By Product Type)
- Spain (By Product Type)
- Scandinavia (By Product Type)
- Rest of Europe (By Product Type)
- Asia Pacific
- By Product Type
- By Application
- By Country
- Japan (By Product Type)
- China (By Product Type)
- Australia (By Product Type)
- India (By Product Type)
- Southeast Asia (By Product Type)
- Rest of Asia Pacific (By Product Type)
- Latin America
- By Product Type
- By Application
- By Country
- Brazil (By Product Type)
- Mexico (By Product Type)
- Rest of Latin America (By Product Type)
- The Middle East & Africa
- By Product Type
- By Application
- By Country
- GCC (By Product Type)
- South Africa (By Product Type)
- Rest of Middle East & Africa (By Product Type)
Table of Content
1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Prevalence of Key Disease Conditions -Key Regions/Country
- 4.2. New Product Launch
- 4.3. Pipeline Analysis
- 4.4. Impact of COVID-19 on the Immunomodulators Market
- 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
5. Global Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Product Type
- 5.2.1. Immunosuppressants
- 5.2.2. Immunostimulants
- 5.3. Market Analysis, Insights and Forecast - By Application
- 5.3.1. Respiratory
- 5.3.2. Oncology
- 5.3.3. Multiple Sclerosis
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By Geography
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast - By Product Type
- 6.2.1. Immunosuppressants
- 6.2.2. Immunostimulants
- 6.3. Market Analysis, Insights and Forecast - By Application
- 6.3.1. Respiratory
- 6.3.2. Oncology
- 6.3.3. Multiple Sclerosis
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.1.1. By Product Type
- 6.4.1.1.1. Immunosuppressants
- 6.4.1.1.2. Immunostimulants
- 6.4.1.1. By Product Type
- 6.4.2. Canada
- 6.4.2.1. By Product Type
- 6.4.2.1.1. Immunosuppressants
- 6.4.2.1.2. Immunostimulants
- 6.4.2.1. By Product Type
- 6.4.1. U.S.
7. Europe Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast - By Product Type
- 7.2.1. Immunosuppressants
- 7.2.2. Immunostimulants
- 7.3. Market Analysis, Insights and Forecast - By Application
- 7.3.1. Respiratory
- 7.3.2. Oncology
- 7.3.3. Multiple Sclerosis
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Product Type
- 7.4.1.1.1. Immunosuppressants
- 7.4.1.1.2. Immunostimulants
- 7.4.1.1. By Product Type
- 7.4.2. Germany
- 7.4.2.1. By Product Type
- 7.4.2.1.1. Immunosuppressants
- 7.4.2.1.2. Immunostimulants
- 7.4.2.1. By Product Type
- 7.4.3. France
- 7.4.3.1. By Product Type
- 7.4.3.1.1. Immunosuppressants
- 7.4.3.1.2. Immunostimulants
- 7.4.3.1. By Product Type
- 7.4.4. Spain
- 7.4.4.1. By Product Type
- 7.4.4.1.1. Immunosuppressants
- 7.4.4.1.2. Immunostimulants
- 7.4.4.1. By Product Type
- 7.4.5. Italy
- 7.4.5.1. By Product Type
- 7.4.5.1.1. Immunosuppressants
- 7.4.5.1.2. Immunostimulants
- 7.4.5.1. By Product Type
- 7.4.6. Scandinavia
- 7.4.6.1. By Product Type
- 7.4.6.1.1. Immunosuppressants
- 7.4.6.1.2. Immunostimulants
- 7.4.6.1. By Product Type
- 7.4.7. Rest of Europe
- 7.4.7.1. By Product Type
- 7.4.7.1.1. Immunosuppressants
- 7.4.7.1.2. Immunostimulants
- 7.4.7.1. By Product Type
- 7.4.1. U.K.
8. Asia Pacific Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast - By Product Type
- 8.2.1. Immunosuppressants
- 8.2.2. Immunostimulants
- 8.3. Market Analysis, Insights and Forecast - By Application
- 8.3.1. Respiratory
- 8.3.2. Oncology
- 8.3.3. Multiple Sclerosis
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Product Type
- 8.4.1.1.1. Immunosuppressants
- 8.4.1.1.2. Immunostimulants
- 8.4.1.1. By Product Type
- 8.4.2. China
- 8.4.2.1. By Product Type
- 8.4.2.1.1. Immunosuppressants
- 8.4.2.1.2. Immunostimulants
- 8.4.2.1. By Product Type
- 8.4.3. India
- 8.4.3.1. By Product Type
- 8.4.3.1.1. Immunosuppressants
- 8.4.3.1.2. Immunostimulants
- 8.4.3.1. By Product Type
- 8.4.4. Australia
- 8.4.4.1. By Product Type
- 8.4.4.1.1. Immunosuppressants
- 8.4.4.1.2. Immunostimulants
- 8.4.4.1. By Product Type
- 8.4.5. Southeast Asia
- 8.4.5.1. By Product Type
- 8.4.5.1.1. Immunosuppressants
- 8.4.5.1.2. Immunostimulants
- 8.4.5.1. By Product Type
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Product Type
- 8.4.6.1.1. Immunosuppressants
- 8.4.6.1.2. Immunostimulants
- 8.4.6.1. By Product Type
- 8.4.1. Japan
9. Latin America Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast - By Product Type
- 9.2.1. Immunosuppressants
- 9.2.2. Immunostimulants
- 9.3. Market Analysis, Insights and Forecast - By Application
- 9.3.1. Respiratory
- 9.3.2. Oncology
- 9.3.3. Multiple Sclerosis
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Product Type
- 9.4.1.1.1. Immunosuppressants
- 9.4.1.1.2. Immunostimulants
- 9.4.1.1. By Product Type
- 9.4.2. Mexico
- 9.4.2.1. By Product Type
- 9.4.2.1.1. Immunosuppressants
- 9.4.2.1.2. Immunostimulants
- 9.4.2.1. By Product Type
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Product Type
- 9.4.3.1.1. Immunosuppressants
- 9.4.3.1.2. Immunostimulants
- 9.4.3.1. By Product Type
- 9.4.1. Brazil
10. Middle East & Africa Immunomodulators Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast - By Product Type
- 10.2.1. Immunosuppressants
- 10.2.2. Immunostimulants
- 10.3. Market Analysis, Insights and Forecast - By Application
- 10.3.1. Respiratory
- 10.3.2. Oncology
- 10.3.3. Multiple Sclerosis
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Product Type
- 10.4.1.1.1. Immunosuppressants
- 10.4.1.1.2. Immunostimulants
- 10.4.1.1. By Product Type
- 10.4.2. South Africa
- 10.4.2.1. By Product Type
- 10.4.2.1.1. Immunosuppressants
- 10.4.2.1.2. Immunostimulants
- 10.4.2.1. By Product Type
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Product Type
- 10.4.3.1.1. Immunosuppressants
- 10.4.3.1.2. Immunostimulants
- 10.4.3.1. By Product Type
- 10.4.1. GCC
11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2025)
- 11.3. Company Profiles
- 11.3.1. F. Hoffmann-La Roche Ltd
- 11.3.1.1. Overview,
- 11.3.1.2. Product Types & Services,
- 11.3.1.3. SWOT Analysis,
- 11.3.1.4. Recent Developments,
- 11.3.1.5. Strategies,
- 11.3.1.6. Financials (Based on Availability)
- 11.3.2. Novartis AG
- 11.3.2.1. Overview,
- 11.3.2.2. Product Types & Services,
- 11.3.2.3. SWOT Analysis,
- 11.3.2.4. Recent Developments,
- 11.3.2.5. Strategies,
- 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Biogen
- 11.3.3.1. Overview,
- 11.3.3.2. Product Types & Services,
- 11.3.3.3. SWOT Analysis,
- 11.3.3.4. Recent Developments,
- 11.3.3.5. Strategies,
- 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Teva Pharmaceutical Industries Ltd.
- 11.3.4.1. Overview,
- 11.3.4.2. Product Types & Services,
- 11.3.4.3. SWOT Analysis,
- 11.3.4.4. Recent Developments,
- 11.3.4.5. Strategies,
- 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Amgen, Inc
- 11.3.5.1. Overview,
- 11.3.5.2. Product Types & Services,
- 11.3.5.3. SWOT Analysis,
- 11.3.5.4. Recent Developments,
- 11.3.5.5. Strategies,
- 11.3.5.6. Financials (Based on Availability)
- 11.3.6. Bristol-Myers & Squibb Company
- 11.3.6.1. Overview,
- 11.3.6.2. Product Types & Services,
- 11.3.6.3. SWOT Analysis,
- 11.3.6.4. Recent Developments,
- 11.3.6.5. Strategies,
- 11.3.6.6. Financials (Based on Availability)
- 11.3.7. Merck Sharp & Dohme Corp.
- 11.3.7.1. Overview,
- 11.3.7.2. Product Types & Services,
- 11.3.7.3. SWOT Analysis,
- 11.3.7.4. Recent Developments,
- 11.3.7.5. Strategies,
- 11.3.7.6. Financials (Based on Availability)
- 11.3.8. Eli Lilly and Company
- 11.3.8.1. Overview,
- 11.3.8.2. Product Types & Services,
- 11.3.8.3. SWOT Analysis,
- 11.3.8.4. Recent Developments,
- 11.3.8.5. Strategies,
- 11.3.8.6. Financials (Based on Availability)
- 11.3.9. Other Prominent Players
- 11.3.9.1. Overview,
- 11.3.9.2. Product Types & Services,
- 11.3.9.3. SWOT Analysis,
- 11.3.9.4. Recent Developments,
- 11.3.9.5. Strategies,
- 11.3.9.6. Financials (Based on Availability)
- 11.3.1. F. Hoffmann-La Roche Ltd
12. Strategic Recommendations
List of Tables
- Table 1: Global Immunomodulators Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 2: Global Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 3: Global Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 4: North America Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 5: North America Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 6: North America Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 7: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 8: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 9: Europe Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 10: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 11: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 12: Asia Pacific Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 13: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 14: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 15: Latin America Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 16: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 17: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
- Table 18: Middle East & Africa Immunomodulators Market Revenue (USD billion) Forecast, by Application, 2021-2034
List of Figures
- Figure 01: Global Immunomodulators Market Value Share (%), by Region, 2025 & 2034
- Figure 02: Global Immunomodulators Market Value Share (%), By Product Type, 2025 & 2034
- Figure 03: Global Immunomodulators Market Forecast (USD billion), By Immunosuppressants, 2025 -2034
- Figure 04: Global Immunomodulators Market Forecast (USD billion), By Immunostimulants, 2025 -2034
- Figure 05: Global Immunomodulators Market Value Share (%), By Application, 2025 & 2034
- Figure 06: Global Immunomodulators Market Forecast (USD billion), By Respiratory, 2025 -2034
- Figure 07: Global Immunomodulators Market Forecast (USD billion), By Oncology, 2025 -2034
- Figure 08: Global Immunomodulators Market Forecast (USD billion), By Multiple Sclerosis, 2025 -2034
- Figure 09: Global Immunomodulators Market Forecast (USD billion), By Others, 2025 -2034
- Figure 10: North America Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
- Figure 11: North America Immunomodulators Market Value Share (%), By Country, 2025
- Figure 12: North America Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
- Figure 13: North America Immunomodulators Market Value Share (%), By Product Type, 2025
- Figure 14: North America Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
- Figure 15: North America Immunomodulators Market Value Share (%), By Application, 2025
- Figure 16: Europe Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
- Figure 17: Europe Immunomodulators Market Value Share (%), By Country, 2025
- Figure 18: Europe Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
- Figure 19: Europe Immunomodulators Market Value Share (%), By Product Type, 2025
- Figure 20: Europe Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
- Figure 21: Europe Immunomodulators Market Value Share (%), By Application, 2025
- Figure 22: Asia Pacific Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
- Figure 23: Asia Pacific Immunomodulators Market Value Share (%), By Country, 2025
- Figure 24: Asia Pacific Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
- Figure 25: Asia Pacific Immunomodulators Market Value Share (%), By Product Type, 2025
- Figure 26: Asia Pacific Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
- Figure 27: Asia Pacific Immunomodulators Market Value Share (%), By Application, 2025
- Figure 28: Latin America Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
- Figure 29: Latin America Immunomodulators Market Value Share (%), By Country, 2025
- Figure 30: Latin America Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
- Figure 31: Latin America Immunomodulators Market Value Share (%), By Product Type, 2025
- Figure 32: Latin America Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
- Figure 33: Latin America Immunomodulators Market Value Share (%), By Application, 2025
- Figure 34: Middle East & Africa Immunomodulators Market Value (USD billion), By Country, 2025 & 2034
- Figure 35: Middle East & Africa Immunomodulators Market Value Share (%), By Country, 2025
- Figure 36: Middle East & Africa Immunomodulators Market Value (USD billion), By Product Type, 2025 & 2034
- Figure 37: Middle East & Africa Immunomodulators Market Value Share (%), By Product Type, 2025
- Figure 38: Middle East & Africa Immunomodulators Market Value (USD billion), By Application, 2025 & 2034
- Figure 39: Middle East & Africa Immunomodulators Market Value Share (%), By Application, 2025
- Figure 40: Global Immunomodulators Market Revenue (%) Share Analysis by Key Players, 2025
